<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653805</url>
  </required_header>
  <id_info>
    <org_study_id>7Z20/036</org_study_id>
    <nct_id>NCT04653805</nct_id>
  </id_info>
  <brief_title>Therapeutic Approach of Cardiovascular Risk Factors in T2DM by Gender</brief_title>
  <official_title>Differences of the Cardiovascular Risk Factors Therapeutic Approach in T2DM Population According to Gender</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordi Gol i Gurina Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jordi Gol i Gurina Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patients with type 2 diabetes mellitus (T2DM) are at 2- to 4-fold higher risk of&#xD;
      cardiovascular mortality compared with non-diabetic subjects. Cardiovascular disease (CVD) is&#xD;
      the main cause of death in almost half of diabetic population in Spain. Female patients with&#xD;
      T2DM have up to 40% excess risk of CVD compared with men and the causes are still unknown. It&#xD;
      is argued that a tight control of cardiovascular risk factors could improve the situation.&#xD;
&#xD;
      Hypothesis: The cardiovascular risk factors management in women with T2DM is different than&#xD;
      in men with T2DM.&#xD;
&#xD;
      Aims: To assess the therapeutic approach of cardiovascular risk factors and the occurrence of&#xD;
      cardiovascular events among women in comparison to men with T2DM.&#xD;
&#xD;
      Methodology: Observational study based on clinical records of primary health care from T2DM&#xD;
      patients in Catalonia (2007-2013).&#xD;
&#xD;
      Source: SIDIAP database. Analysis: The two study groups (women and men) will be matched to&#xD;
      ensure balance in terms of basal comorbidities and previous cardiovascular disease in order&#xD;
      to describe the study group characteristics and to perform a multivariate modeling approach.&#xD;
&#xD;
      Applicability and Relevance: This study is intended to serve to identify the points of&#xD;
      improvement of the cardiovascular risk factors therapeutic approach in women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Age</measure>
    <time_frame>2007-2013</time_frame>
    <description>Age registered on the date of data extraction (DTALL-30Jun)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender</measure>
    <time_frame>2007-2013</time_frame>
    <description>Gender registered on the date of data extraction (DTALL-30Jun)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Date of DM diagnosis</measure>
    <time_frame>2007-2013</time_frame>
    <description>DM onset date registered on the date of data extraction (DTALL-30Jun)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis of the most common cardiovascular risk factors</measure>
    <time_frame>2007-2013</time_frame>
    <description>High Blood Pressure (&gt;140/90mm Hg), Dyslipidaemia, Smoking and Obesity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of of glycated haemoglobin (HbA1c)</measure>
    <time_frame>2007-2013</time_frame>
    <description>The value closer and prior to data extraction (DTALL-30Jun) will be considered and a window of up to a year before the DTALL accepted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average of the three last measurements of systolic and diastolic blood pressure</measure>
    <time_frame>2007-2013</time_frame>
    <description>A window of up to a year before the DTALL date will be accepted. If there are no 3BP measurements, the ones available closer to DTALL will be accepted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Total Cholesterol (TC), LDL Cholesterol (LDL-C), HDL Cholesterol (HDL-C) and triglycerides (TGC)</measure>
    <time_frame>2007-2013</time_frame>
    <description>A window of up to a year before the DTALL date will be accepted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>2007-2013</time_frame>
    <description>A window of up to a year before the DTALL-30Jun will be accepted. Height will be measured in m and weight in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney function: glomerular filtration estimated by MDRD</measure>
    <time_frame>2007-2013</time_frame>
    <description>The value closer and prior to data extraction (DTALL-30Jun) will be considered and a window of up to a year before the DTALL accepted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney function: urinary albumin excretion (albumin/creatinine ratio)</measure>
    <time_frame>2007-2013</time_frame>
    <description>The value closer and prior to data extraction (DTALL-30Jun) will be considered and a window of up to a year before the DTALL accepted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of hypoglycaemic agents and insulin on the DTALL-30Jun</measure>
    <time_frame>2007-2013</time_frame>
    <description>Data of use will be obtained from the pharmacy billing of the Catalan Health Service (CatSalut).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of antihypertensive, hypolipidemic, antiplatelet and anticoagulant agents on the DTALL-30Jun</measure>
    <time_frame>2007-2013</time_frame>
    <description>Data of use will be obtained from the pharmacy billing of the Catalan Health Service (CatSalut)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular disease registered on the DTALL-30Jun</measure>
    <time_frame>2007-2013</time_frame>
    <description>Coronary artery disease, cerebrovascular disease and peripheral artery disease with codes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Causes of mortality in the population with type 2 diabetes during the study period</measure>
    <time_frame>2007-2013</time_frame>
    <description>Causes of mortality in the population with type 2 diabetes during the study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis of Diabetic retinopathy</measure>
    <time_frame>2007-2013</time_frame>
    <description>Diagnosis of Diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of visits with the primary care team in the previous 12 months</measure>
    <time_frame>2007-2013</time_frame>
    <description>A window of up to a year before the DTALL-30Jun will be considered</description>
  </primary_outcome>
  <enrollment type="Actual">300000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Gender</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Current clinical practice in primary care of patients with type 2 diabetes mellitus</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population is selected from 5,8 million people from the 282 primary care centres of&#xD;
        the Catalan Health Service identified with an anonymized personal identifier and included&#xD;
        in a unique patient registry called &quot;SIDIAP&quot; for primary care in Catalonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients &gt; 30 years of age with a clinical record in the SIDIAP&#xD;
             database.&#xD;
&#xD;
          -  Patients with a diagnosis of type 2 diabetes (codes ICD10: E11, E11.0-E11.9, E14,&#xD;
             E14.0-E14.9) on DTALL-30Jun of each year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients with a diagnosis of type 1 diabetes (E10), gestational diabetes (O24), secondary&#xD;
        diabetes (E12) or any other type of diabetes (E13)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didac Mauricio Puente, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Ramirez-Morros, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català de la Salut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDIAP Jordi Gol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

